07
July 2020
Legal and Privacy Statements
COVID-19 Scientific Webinar Series
1st Webinar
Coagulopathy in COVID-19
15:00 - 16:15 CET
Welcome and introduction
Prof. Nicole Juffermans
Thrombotic and haemostatic issues in intensive care, which challenges do we face and what the biomarkers tell us
13:30-13:45
Prof. Edwin J.R. van Beek
Role of Radiology and plasma D-dimer in pathophysiological aspects and treatment of COVID-19
13:30-13:45
Dr. Michelle Sholzberg
Anticoagulation & therapeutic management :
Which treatment fits best and how can we monitor?
Which treatment fits best and how can we monitor?
13:30-13:45
Q& session
2nd Webinar
Lorem ipsum 08 July 2020
15:00 - 16:15 CET
Welcome and introduction
Prof. James Januzzi
Is a member of the Massachusetts General Hospital Cardiology Division. He is the Hutter Family Professor of Medicine at Harvard Medical School and is on faculty at the Harvard Clinical Research Institute
13:30-13:45
Dr. Raphael Twerenbold
Is an interventional cardiologist and senior physician at the Clinic for Cardiology at the University Hospital Basel
13:30-13:45
Prof. Alexandre Mebazaa
Is Professor of Anaesthesiology and Critical Care Medicine at the Hôpital Lariboisière, University Paris 7, France
13:30-13:45
Dr. Zhou Ning
Associate Professor, Division of Cardiology, Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology
13:30-13:45
Q& session
3rd Webinar
Lorem ipsum 14 July 2020
15:00 - 16:15 CET
Welcome and introduction
W. Conrad Liles
MD, PhD, University of Washington, Seattle, US
13:30-13:45
Tobias Weinberger
MD, Ludwig Maximilian University of Munich, Munich, Germany
13:30-13:45
Q& session
4th Webinar
Lorem ipsum 16 July 2020
15:00 - 16:15 CET
Welcome and introduction
Prof. Anna Kajdy
Head of Obstetrics Department, St. Sophie's Obstetrics and Gynecology Hospital, Warsaw, Poland
13:30-13:45
Prof. Liona Poon
Clinical Professor, Obstetrics, CUHK, Hong Kong
13:30-13:45
Q& session
#Covid19Webinar
Coagulopathy in COVID-19
Coagulopathy in COVID-19: Which challenges do we face in the area of Coagulation.
SARS-CoV-2 has caused a pandemic with high mortality and is commonly complicated with coagulopathy, which is one of the most significant poor prognostic features of the disease.
Systemic coagulation activation and thrombotic complications, such as venous thromboembolism, emerged as an important consideration in the management of patients.
Experts around the globe are heavily seeking to understand the pathophysiological aspects and to provide guidance in therapy.
In this webinar, which will focus entirely on topics related to the field of Coagulation,
#Covid19Webinar
08 July 2020 Webinar
Coagulopathy in COVID-19: Which challenges do we face in the area of Coagulation.
SARS-CoV-2 has caused a pandemic with high mortality and is commonly complicated with coagulopathy, which is one of the most significant poor prognostic features of the disease.
Systemic coagulation activation and thrombotic complications, such as venous thromboembolism, emerged as an important consideration in the management of patients.
Experts around the globe are heavily seeking to understand the pathophysiological aspects and to provide guidance in therapy.
In this webinar, which will focus entirely on topics related to the field of Coagulation,
#Covid19Webinar
14 July 2020 Webinar
Coagulopathy in COVID-19: Which challenges do we face in the area of Coagulation.
SARS-CoV-2 has caused a pandemic with high mortality and is commonly complicated with coagulopathy, which is one of the most significant poor prognostic features of the disease.
Systemic coagulation activation and thrombotic complications, such as venous thromboembolism, emerged as an important consideration in the management of patients.
Experts around the globe are heavily seeking to understand the pathophysiological aspects and to provide guidance in therapy.
In this webinar, which will focus entirely on topics related to the field of Coagulation,
SARS-CoV-2 has caused a pandemic with high mortality and is commonly complicated with coagulopathy, which is one of the most significant poor prognostic features of the disease.
SARS-CoV-2 has caused a pandemic with high mortality and is commonly complicated with coagulopathy, which is one of the most significant poor prognostic features of the disease.
#Covid19Webinar
16 July 2020 Webinar
Coagulopathy in COVID-19: Which challenges do we face in the area of Coagulation.
SARS-CoV-2 has caused a pandemic with high mortality and is commonly complicated with coagulopathy, which is one of the most significant poor prognostic features of the disease.
Systemic coagulation activation and thrombotic complications, such as venous thromboembolism, emerged as an important consideration in the management of patients.
Experts around the globe are heavily seeking to understand the pathophysiological aspects and to provide guidance in therapy.
In this webinar, which will focus entirely on topics related to the field of Coagulation,
Meet the Speakers
This section of the site will provide background information
on the panellists, their profiles, and accomplishments.
on the panellists, their profiles, and accomplishments.
Prof. Saskia Middeldorp
Prof. Nicole Juffermans
Prof. Edwin J.R. van Beek
Dr. Michelle Sholzberg
Prof. James Januzzi
Dr. Raphael Twerenbold
Prof. Alexandre Mebazaa
Dr. Zhou Ning
W. Conrad Liles
Tobias Weinberger
Internist and Professor of medicine at the department of vascular medicine, Amsterdam UMC, the Netherlands, as the chair, will guide us through the webinar and introduce us to the topic and the speakers.
Intensivist and professor of Intensive Care Medicine at the University of Amsterdam, will provide us an insight on the thrombotic and haemostatic issues in intensive care.
SINAPSE Chair of Clinical Radiology and Director of Edinburgh Imaging facility QMRI from the University of Edinburgh will talk about the pathophysiological aspects of COVID-19, as well as the role of D-dimer in prognosis for thrombosis and imaging workup.
Medical Director of the Coagulation Laboratory at St. Michael’s Hospital in Toronto, Ontario, Canada and Principal Investigator on the RAPID-COVID COAG Study will present the landscape of state of the art anticoagulation therapies and their pros and cons.
Hutter Family Professor of Medicine at Harvard Medical School and is on faculty at the Harvard Clinical Research Institute
Interventional cardiologist and senior physician at the Clinic for Cardiology at the University Hospital Basel
Professor of Anaesthesiology and Critical Care Medicine at the Hôpital Lariboisière, University Paris 7, France
Associate Professor, Division of Cardiology, Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology
MD, PhD, University of Washington, Seattle, US
Lorem ipsum dolor
Lorem ipsum dolor sit amet, consectetur adipiscing elit.
Integer iaculis vehicula minec aliquet.
Ut laoreetvenenatis erat, nec mollisnunc laoreet sed.
Integer iaculis vehicula minec aliquet.
Ut laoreetvenenatis erat, nec mollisnunc laoreet sed.
Missed the last one? Watch it again!
Archive of the Previous sessions. Cut downs and highlights of the different segments of the webinars.
This section is activated after the first webinar.
This section is activated after the first webinar.
1st Webinar
Coagulopathy in COVID-19
07/07/2020
2nd Webinar
Coagulopathy in COVID-19
22/09/2020
3st Webinar
Coagulopathy in COVID-19
14/07/2020
This website contains information on products which is targeted to a wide range of audiences and could contain product details or information otherwise not accessible, approved or valid in your country. Please be aware that we do not take any responsibility for accessing those information which may not comply with any legal process, regulation, registration or usage in the country of your origin. Please also be aware that the information in this website should not be used to diagnose, treat, cure or prevent any disease without the advice of a qualified medical professional, and does not replace medical advice or a medical examination.